Consequently, a decrease in the efficacy of NAC has been shown in hormone receptor-positive (HR+) breast cancer, leading to ongoing debates regarding the appropriateness of utilizing NAC in this particular patient population. This evidence concerns the gene NR4A1 and breast cancer.